Corbus Pharmaceuticals Holdings Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Corbus Pharmaceuticals Holdings hat ein Gesamteigenkapital von $97.0M und eine Gesamtverschuldung von $13.0M, was einen Verschuldungsgrad von 13.4% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $125.7M bzw. $28.8M.

Wichtige Informationen

13.4%

Verhältnis von Schulden zu Eigenkapital

US$12.95m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$120.10m
Eigenkapital	US$96.97m
Gesamtverbindlichkeiten	US$28.78m
Gesamtvermögen	US$125.74m

Jüngste Berichte zur Finanzlage

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?

Nov 19

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

Feb 04

Recent updates

Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely

Jun 12

Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?

May 14

What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?

Mar 11

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

Feb 04

Corbus Pharmaceuticals: Down But Not Out

Jan 29

Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?

Jan 09

Corbus's lenabasum shows benefit in autoimmune disorder

Nov 09

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: CRBPDie kurzfristigen Aktiva des Unternehmens ($121.7M) übersteigen seine kurzfristigen Passiva ($25.9M).

Langfristige Verbindlichkeiten: CRBPDie kurzfristigen Vermögenswerte des Unternehmens ($121.7M) übersteigen seine langfristigen Verbindlichkeiten ($2.9M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: CRBP über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: CRBPDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0.6% auf 13.4% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: CRBP auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: CRBP über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 0.1% pro Jahr zurückgeht

Corbus Pharmaceuticals Holdings Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

Corbus Pharmaceuticals Holdings Gets a 180-Day Extension to January 2, 2023, to Regain Compliance with the Minimum Bid Price Requirement

Corbus Pharmaceuticals Holdings Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

Recent updates

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering.

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002)

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

New minor risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

New minor risk - Shareholder dilution

Price target increased to US$2.20

Corbus Pharmaceuticals Holdings, Inc. Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Appoints Anne Altmeyer to Board of Directors

First half 2022 earnings released

Corbus Pharmaceuticals GAAP EPS of -$0.11

Corbus Pharmaceuticals Holdings Gets a 180-Day Extension to January 2, 2023, to Regain Compliance with the Minimum Bid Price Requirement

Price target increased to US$2.20

Corbus Pharmaceuticals Holdings, Inc. Enters into a Binding Term Sheet with Venn Therapeutics, LLC, to Resolve the Claims by Venn Against the Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Announces That New Preclinical Data for CRB-601 Are Being Presented in an Oral Presentation At the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference in New York

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 18, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$1.65

Corbus Pharmaceuticals Holdings Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?

Third quarter 2021 earnings released: US$0.017 loss per share (vs US$0.43 loss in 3Q 2020)

Head of Research & Chief Medical Officer Barbara White has left the company

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.52 loss in 2Q 2020)

Consensus revenue estimates fall to US$2.32m

Corbus Pharmaceuticals Holdings, Inc.(NasdaqGM:CRBP) dropped from Russell 3000E Growth Index

Corbus Pharmaceuticals Announces Topline Results from Determine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely

Corbus Pharmaceuticals Holdings, Inc. Announces Licensing Deals for Two New Monoclonal Antibodies, CRB-601 and CRB-602 to Further Expand Pipeline into Cancer and Fibrotic Diseases

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.43 loss in 1Q 2020)

Consensus revenue estimates increase to US$3.68m

Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?

Consensus forecasts updated

Full year 2020 earnings released: US$1.42 loss per share (vs US$1.12 loss in FY 2019)

Corbus Pharmaceuticals Holdings, Inc. Provides Clinical Program Updates

What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?

Corbus Pharmaceuticals Holdings, Inc. to Report Q4, 2020 Results on Mar 15, 2021

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

New 90-day high: US$2.58

Corbus Pharmaceuticals: Down But Not Out

New 90-day high: US$1.61

Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?

Price target lowered to US$1.88

Corbus Pharmaceuticals Holdings, Inc. Announces the Resignation of Robert Discordia as Chief Operating Officer

Corbus Pharmaceuticals Holdings, Inc. Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis

Corbus's lenabasum shows benefit in autoimmune disorder

Corbus Pharmaceuticals Holdings, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Robert Discordia Will No Longer Serve as Chief Operating Officer of Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

New 90-day low: US$1.21

Price target lowered to US$15.00

New 90-day high - US$8.63

Corbus Pharmaceuticals Holdings, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Analyse der Finanzlage